Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Todd Berard, Chief Marketing Officer of Biolife Solutions (NASDAQ:BLFS), sold 289 shares of common stock on October 9, 2025, at a price of $27.36, for a total transaction value of $7907. Following the transaction, Berard directly owns 133,617 shares of Biolife Solutions. The sale comes as BLFS trades near its 52-week high of $29.55, with the stock showing strong momentum, up 24% over the past six months. According to InvestingPro data, the company has demonstrated robust revenue growth of 68% and maintains a healthy liquidity position with a current ratio of 4.43.
In other recent news, BioLife Solutions reported its second-quarter 2025 earnings, showcasing a revenue of $25.42 million, marking a 29% increase year-over-year and surpassing expectations. Despite this positive revenue surprise, the company reported a net loss of $15.8 million, or $0.33 per share, which was larger than anticipated due to a $15.5 million in-process R&D expense related to the PanTHERA transaction. In a strategic move, BioLife Solutions sold its cold chain logistics subsidiary, SAVSU Cleo Technologies, to Peli BioThermal for $25.5 million in cash. Analyst firm H.C. Wainwright responded by raising its price target for BioLife Solutions from $30 to $32, maintaining a Buy rating. KeyBanc also reiterated its Overweight rating on the company, citing potential growth avenues to achieve a long-term revenue target exceeding $250 million by 2030. Meanwhile, during the company’s 2025 annual meeting, shareholders re-elected all seven board members and approved executive compensation and the appointment of Grant Thornton LLP as the independent auditor. These developments reflect a mix of strategic adjustments and continued investor confidence in BioLife Solutions’ future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.